← SynDRA
LIFITEGRAST
SynDRA canonical compound SYN0029430 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | ICAM1 | ITGAL |
|---|
| Mechanism of action | lymphocyte function-associated antigen negative modulator |
|---|
| Indication | dry eye syndrome |
|---|
| Disease area | ophthalmology |
|---|
All known targets
Mechanisms of action (all sources)
- ITGAL ANTAGONIST
- Integrin alpha-L/beta-2 (LFA-1) antagonist
- ITGB2 ANTAGONIST
- lymphocyte function-associated antigen negative modulator
- ICAM1 INHIBITOR
- ITGAL MODULATOR
Drug classes
- Ophthalmic Solutions
- Pharmaceutical Solutions
- Lymphocyte Function-Associated Antigen-1 Antagonists
- Lymphocyte Function-Associated Antigen-1 Antagonist
ATC classes
- S01X · OTHER OPHTHALMOLOGICALS
Cross-references
Synonyms
- SAR 1118-023
- SAR-1118
- xiidra
- SHP-606
- SHP606
- Xiidra
- SAR 1118
- UNII-038E5L962W
- CHEMBL2048028
- 038E5L962W
- (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid
- (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid
- SAR-1119
- SPD606
- CHEBI:133023
- lifitegrastum
- RefChem:57036
- DTXCID6067836
- S01XA25
- MFCD28502439
- Lifitegrast(SAR 1118)
- Lifitegrast [USAN:INN]
- C29H24Cl2N2O7S
- Xiidra (TN)
- Lifitegrast (Standard)
- LIFITEGRAST [MI]
- LIFITEGRAST [INN]
- Lifitegrast (USAN/INN)
- LIFITEGRAST [USAN]
- Lifitegrast; SAR 1118
- LIFITEGRAST [WHO-DD]
- GTPL7533
- orb1303486
- SCHEMBL2632068
- SCHEMBL29355715
- SCHEMBL29386183
- LIFITEGRAST [ORANGE BOOK]
- SAR1118
Reported adverse events
- Eye swelling
- Hypersensitivity
Look up LIFITEGRAST in the interactive SynDRA portal →